1. Home
  2. SOS vs RNAZ Comparison

SOS vs RNAZ Comparison

Compare SOS & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

HOLD

Current Price

$1.12

Market Cap

9.9M

Sector

Finance

ML Signal

HOLD

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$7.08

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOS
RNAZ
Founded
2004
2016
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
8.0M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
SOS
RNAZ
Price
$1.12
$7.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.5K
6.5K
Earning Date
05-15-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$6.08
52 Week High
$8.92
$20.99

Technical Indicators

Market Signals
Indicator
SOS
RNAZ
Relative Strength Index (RSI) 47.16 27.01
Support Level $1.06 $6.08
Resistance Level $1.56 $9.37
Average True Range (ATR) 0.07 0.60
MACD -0.00 -0.12
Stochastic Oscillator 28.67 3.57

Price Performance

Historical Comparison
SOS
RNAZ

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: